baby treated for a rare genetic disorder, CPS1 deficiency, with a CRISPR base editing therapy in LNPs. Children's Hospital of Philadelphia and UPenn researchers. they came up with a brand new gene editing therapy and got FDA approval in 6 months. two IV infusions seem to have fully done the trick!